Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp28204_8k.htm |
Exhibit 99.01
|
Press Release
|
 |
|
www.shire.com
|
Notification of major interests in shares
January 23, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
|
2. Reason for the notification
|
State
Yes/No
|
|
An acquisition or disposal of voting rights
|
Yes
|
|
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
|
|
|
An event changing the breakdown of voting rights
|
|
|
|
|
3. Full name of person(s) subject to the notification obligation:
|
Capital Group International, Inc.
|
|
4. Full name of shareholder(s) (if different from 3.):
|
|
|
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
|
19 January 2012
|
|
6. Date on which issuer notified:
|
20 January 2012
|
|
7. Threshold(s) that is/are crossed or reached:
|
Below 3%
|
|
8. Notified details:
|
|
A: Voting rights attached to shares
|
Class/type of shares
if possible using the ISIN CODE
|
Situation previous to
the Triggering
transaction
|
Resulting situation after the triggering
transaction
|
||||||
|
Number
of
Shares
|
Number
of
Voting
Rights
|
Number
of
shares
|
Number of voting
rights
|
% of voting
rights
|
||||
|
Direct
|
Indirect
|
Direct
|
Indirect
|
Direct
|
Indirect
|
|||
|
Ordinary
(JE00B2QKY057)
|
9,826,842
|
9,826,842
|
9,789,761
|
9,789,761
|
1.7405%
|
|||
|
ADR
(US82481R1068)
|
2,357,837
|
7,073,511
|
2,355,937
|
7,067,811
|
1.2566%
|
|||
B: Financial Instruments
Resulting situation after the triggering transaction
|
Type of financial
instrument
|
Expiration
date
|
Exercise/Conversion
Period/ Date
|
Number of voting
rights that may be
acquired if the instrument
is exercised/converted
|
% of voting
rights
|
|
n/a
|
|
|
|
|
|
Total (A+B)
|
|
|
Number of voting rights
|
% of voting rights
|
|
16,857,572
|
2.9971%
|
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
|
Number of Shares
|
Percent of Outstanding
|
|
|
Capital Group International, Inc. ("CGII") holdings
|
16,857,572
|
2.9971%
|
|
Holdings by CGII Management Companies and Funds:
|
||
|
• Capital Guardian Trust Company
|
14,035,752
|
2.4954%
|
|
• Capital International Limited
|
1,220,841
|
0.2170%
|
|
• Capital International SÁrl
|
293,119
|
0.0521%
|
|
• Capital International, Inc.
|
1,307,860
|
0.2325%
|
Proxy Voting:
|
10. Name of the proxy holder:
|
N/A
|
|
11. Number of voting rights proxy holder will cease to hold:
|
N/A
|
|
12. Date on which proxy holder will cease to hold voting rights:
|
N/A
|
|
13. Additional information:
|
Notification using the total voting rights figures of
562,472,830
|
|
14. Contact name:
|
Vivien Tan
|
|
15. Contact telephone number:
|
(213) 615-0469
|
Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, +44 1256 894746
For further information please contact:
|
Investor Relations
|
Eric Rojas (erojas@shire.com)
|
+1 781 482 0999
|
|
Sarah Elton-Farr (seltonfarr@shire.com)
|
+44 1256 894157
|
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.